

IN THE CLAIMS:

Please cancel claims 58, 59 and 63-65 without prejudice.

Please amend the claims 39, 56, 57 and 60-62 as follows:

---

39. (amended) A method for finding drug development targets for obesity, osteoporosis, diabetes, osteoarthritis or hypertension comprising;  
measuring the level of each protein in a proteome of a body fluid containing protein from a subject having a disease state of obesity, osteoporosis, diabetes, osteoarthritis or hypertension,

D2 comparing the level of each protein to the level in a control body fluid,  
determining which proteins are found in a statistically significant different amount compared to the control thereby indicating them to be protein markers, and  
determining which of the protein markers is involved in the same metabolic pathway as said disease state, thereby indicating these to be drug development targets.

---

56. (amended) The method of claim 39 wherein said body fluid and said control body fluid are from one or more genetically identical individuals.

D3 57. (amended) The method of claim 56 wherein the individuals are a human.

---

60. (amended) A method of identifying markers diagnostic, prognostic, indicative of appropriate therapy for a disease state or monitoring response to therapy, comprising;

- D4 a) obtaining a body fluid from a subject having a disease state of obesity, osteoporosis, diabetes, osteoarthritis or hypertension,  
b) determining levels of proteins in the proteome in said body fluid,

BEST AVAILABLE COPY

c) comparing the levels of each protein in said proteome to levels of a corresponding protein in a control body fluid from a subject not having the disease state or a control standard,

d) determining which proteins have statistically significantly higher or lower levels in each body fluid,

wherein said markers have a statistically significantly higher or lower level in a comparison between the two body fluid.

D4  
cont

61. (amended) The method of claim 60 wherein said body fluid and said control body fluid are from one or more genetically identical individuals.

63. (amended) The method of claim 61 wherein the individuals are human.

---

Please add the following claims 66-77.

66. The method of claim 39 wherein statistically significant is determined as a  $p<0.01$ .

67. The method of claim 66 wherein statistically significant is determined as a  $p<0.001$ .

68. The method of claim 60 wherein statistically significant is determined as a  $p<0.01$ .

69. The method of claim 68 wherein statistically significant is determined as a  $p<0.001$ .

70. The method of claim 39 wherein the disease state is obesity, osteoporosis, diabetes or osteoarthritis.

71. The method of claim 60 wherein the disease state is obesity, osteoporosis, diabetes or osteoarthritis.

72. The method of claim 39 further comprising fractionating the body fluid before said measuring the level of each protein in a proteome.

73. The method of claim 72 wherein said fractionating specifically removes one or more preselected proteins from the body fluid.

DS  
Cont'd

74. The method of claim 60 further comprising fractionating the body fluid before said determining levels of proteins in the proteome.

75. The method of claim 74 wherein said fractionating specifically removes one or more preselected proteins from the body fluid.

76. The method of claim 39 wherein the body fluid is a fraction of blood.

77. The method of claim 60 wherein the body fluid is a fraction of blood.

---

#### REMARKS

Claims 39, 56, 57, 60-62 and 66-77 are pending. Claims 58, 59 and 63-65 have been canceled without prejudice. Support for the amendments is found on pages 11, 24, 27 and Example 2 among other locations throughout the specification. Reconsideration of the rejection is respectfully requested.

The specification was objected to because the title was allegedly not descriptive. The title has been amended to more closely resemble the present claims.

The examiner has noted a blank on page 39 of the specification. Page 39 has been amended to complete the serial number and to update the status of those applications as issued U.S. Patents.